Highlights of the Program
2 days business program:
Learn from real-world case studies by industry leaders.
SHOWCASING INNOVATION:
Discover the latest technology and techniques from across the industry.
leaders talk:
Hear from top-level experts about how to stay ahead in a fast-changing industry.
MULTIPLE STREAMS:
A business program that is multi-disciplinary, giving you a broad view of the industry.
SMART TECHNOLOGIES:
Explore the latest smart and AI-driven solutions, and see how they can be used in your business.
roundtable discussion:
Join talks with industry peers. Share ideas, make connections, and find new partners.
Program
Day 1 :
MONDAY, FEBRUARY 23, 2026
08:00 - 09:00
REGISTRATION AND MORNING REFRESHMENTS
09:00 - 09:10
OPENING ADDRESS
09:10 - 09:35
INJECTING INNOVATION: HUMAN AND SCIENTIFIC REALITIES IN LARGE-VOLUME SUBCUTANEOUS DRUG DELIVERY
Haydon DuMond
Enable Injections, Inc.
- Reframing industry views on large-volume SC limits and how they can stifle innovation
- Examining clinician perspectives on large-volume SC options and bioavailability impacts
- Navigating formulation challenges in large-volume SC delivery that increase time, costs, and risks
09:35 - 09:40
Q&A SESSION ON LARGE-VOLUME SUBCUTANEOUS DRUG DELIVERY
09:40 - 10:05
SUBCUTANEOUS DELIVERY OF BIOLOGICS AND ADCs: LESSONS, PATHWAYS, AND DEVICES
Charles Theuer
Halozyme
- Utilizing subcutaneous Ab administration experience to guide delivery strategies of ADCs at scale
- Documenting clinical development pathways for approval of subcutaneously delivered biologics
- Permitting rapid 10 ml SC dosing using hyaluronidase with high-volume autoinjectors
10:05 - 10:10
Q&A SESSION ON SUBCUTANEOUS DELIVERY OF BIOLOGICS AND ADCS
10:10 - 10:35
ENABLING DELIVERY OF COMPLEX BIOLOGICS: NAVIGATING THROUGH THE OPPORTUNITIES AND CHALLENGES OF HIGH-DOSE DELIVERY
Nick Carrara
BD
- Forecasting how rising subcutaneous biologics reshape markets, with emphasis on high-dose therapy
- Appraising device options for subcutaneous delivery, focusing on key high-dose design considerations
- Co-developing combination products with device partners to reduce risks and speed development
10:35 - 10:40
Q&A SESSION ON HIGH-DOSE SUBCUTANEOUS BIOLOGICS DELIVERY
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
Sponsored By NOF AMERICA CORPORATION
11:00 - 11:30
PANEL DISCUSSION ON PRECISION MEDICINE: ENCAPSULATION TECHNIQUES FOR TARGETED DRUG DELIVERY
- Benchmarking scale-up readiness with fit-for-purpose assays before introducing targeting into optimized encapsulated formulations
- Timing precision medicine integration using gastric retentive oral delivery to enhance efficacy and limit adverse effects
- Triggering nucleic acid activity in target cells via ligand guidance, activation switches, and receptor-mediated BBB transport
| NOF CORPORATION | Moderator
| Next Phase Analytix
| Overseas Pharmaceuticals
| Forta Bio, Inc.
11:30 - 11:55
LEAVING THE ICE AGE – STABILIZATION OF VIRAL VECTORS TO CIRCUMVENT FROZEN STORAGE
Cornelius Pompe
Leukocare AG
- Overcoming frozen storage barriers hindering reliable and scalable viral vector supply chains
- Applying an integrated analytical toolkit with data science to identify stability determinants
- Showcasing case studies enabling robust non-frozen formulations for clinical and commercial use
11:55 - 12:00
Q&A SESSION ON NON-FROZEN STABILIZATION OF VIRAL VECTORS WITH ANALYTICS
12:00 - 12:25
BIOAVAILABILITY ENHANCEMENT STRATEGIES FOR TARGETED PROTEIN DEGRADERS
Rebecca Coutts
PCI Pharma Services
- Catalyzing oral TPD bioavailability with hot melt extrusion, spray drying, and nanotechnology
- Partnering via product-first, platform-agnostic teams for integrated end-to-end solutions
- Centralizing proof of concept through clinical supply to streamline communication and continuity
12:25 - 12:30
Q&A SESSION ON ORAL BIOAVAILABILITY OF TARGETED PROTEIN DEGRADERS
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE DRUG DELIVERY EXHIBITION
13:30 - 13:55
ADVANCING EXTRAHEPATIC TARGETED DELIVERY TO ACCELERATE DEVELOPMENT OF NUCLEIC ACID THERAPEUTICS
Weixia Zhang
WuXi AppTec
- Tuning lipid composition and processing to target lung, spleen, or lymph nodes beyond the liver
- Appending anti-CD3 or anti-CD8 antibodies to steer LNPs to T-cells and limit liver uptake
- Generating selective T-cell uptake with CD19 CAR circRNA LNPs for durable expression and activity
13:55 - 14:00
Q&A SESSION ON EXTRAHEPATIC LNP TARGETING TO T CELLS
14:00 - 14:25
INNOVATIVE DELIVERY STRATEGIES FOR INSOLUBLE AND NUCLEOSIDE-BASED THERAPEUTICS: BRIDGING SMALL MOLECULES AND RNA DRUGS
James Carroll
RNA NanoBiotics, Inc.
- Formulating insoluble oncology agents like SN-38 via nano and conjugate approaches for better uptake
- Co-delivering RNA therapeutics with nucleoside analogs to improve targeting and reduce toxicity
- Streamlining translation via nanoparticles, conjugates, and 505(b)(2) pathways for faster trials
14:25 - 14:30
Q&A SESSION ON STRATEGIES FOR DELIVERY OF INSOLUBLE AGENTS
14:30 - 14:55
DRUG PRODUCT DESIGN ENABLING RAPID AND SCALABLE CLINICAL DEVELOPMENT
Nick Montalbano
Serán BioScience, LLC
- Calibrating risk-based design to align API, intermediates, dosage form, and patient needs
- Recognizing particle and powder properties as drivers of bioperformance and manufacturability
- Anticipating scalable ASD design by using early particle insights from FIH through commercialization
- Scaling conventional products by tracking size and morphology changes to cut risks, time, and costs
14:55 - 15:00
Q&A SESSION ON SCALABLE DRUG PRODUCT DESIGN FOR CLINICAL DEVELOPMENT
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
Sponsored By SERÁN BIOSCIENCE, LLC
15:30 - 15:55
CUSTOM POLOXAMERS FOR ENHANCED FORMULATION AND DELIVERY OF APIs
Ashish Joshi
BASF
- Introducing BASF’s GMP Solution Center in Wyandotte and its custom poloxamer manufacturing capabilities
- Tailoring poloxamer grades to enhance API solubility and improve delivery in challenging formulations
- Presenting case examples of custom poloxamers developed to address key industry challenges
15:55 - 16:00
Q&A SESSION ON CUSTOM POLOXAMERS FOR APIs
16:00 - 16:25
DECISION-MAKING FRAMEWORKS: TO GUIDE ORAL BIOAVAILABILITY-ENHANCING TECHNOLOGY SELECTION
Tyler Clikeman
Catalent Pharma Solutions
- Guiding technology choice for amorphous dispersions, lipid systems, cyclodextrins, and micronization
- Integrating empirical and mechanistic models with dissolution tools to predict bioavailability
- Diagnosing rate-limiting absorption for small molecules and beyond-Rule-of-Five compounds
- Avoiding improper dosing of enhanced formulations to reduce risk and variability
16:25 - 16:30
Q&A SESSION ON BIOAVAILABILITY ENHANCING TECHNOLOGIES
16:30 - 16:55
GO WITH THE NASAL FLOW: HOW A NOSE PLUG COULD REVOLUTIONIZE TODAY'S SUBOPTIMAL NASAL DELIVERY METHODS
Peter Åhnblad
Hogne AB
- Resolving core limitations of today’s nasal delivery to improve dosing, coverage, and comfort
- Converting the nose into a controlled delivery gateway with an ergonomic, easy-to-use nose plug
- Reimagining nasal flow using nose plugs to enable next-generation intranasal delivery devices
16:55 - 17:00
Q&A SESSION ON FLOW-DIRECTED NASAL DELIVERY WITH NOSE PLUGS
17:00 - 18:00
NETWORKING DRINKS RECEPTION
Day 2 :
TUESDAY, FEBRUARY 24, 2026
08:30 - 09:00
MORNING REFRESHMENTS
09:00 - 09:10
OPENING ADDRESS
09:10 - 09:35
MAKING BIOLOGICS AND NANOPARTICLES INTO MAGIC BULLETS PENETRATING THE BARRIER TO PRECISION IMAGING AND THERAPY
Jan Schnitzer
Proteogenomics Research Institute for Systems Medicine
- Uncovering why passive transvascular delivery hinders small molecules, antibodies, and nanoparticles
- Mapping endothelial barrier targets across organs to guide precise tissue entry and penetration
- Creating "magic bullets" via caveolae immunotargeting to concentrate >50% of the dose in one tissue
09:35 - 09:40
Q&A SESSION ON DRUG DELIVERY ACROSS BLOOD–TISSUE BARRIERS
09:40 - 10:05
TRACKING THE FATE OF BIODEGRADABLE LNPs IN VIVO
Syed Reza
NOF CORPORATION
- Elucidating how highly biodegradable lipids can improve tolerability and therapeutic potency
- Overcoming in vivo tracking hurdles from labile lipids and metabolites unsuitable for detection
- Measuring metabolism and excretion with a bioanalytical approach that resolves detection gaps
10:05 - 10:10
Q&A SESSION ON IN VIVO LNP TRACKING AND BIOANALYTICS
10:10 - 10:35
USING XERIS’ XERIJECT FORMULATION PLATFORM FOR LARGE MOLECULE PARENTERAL DRUG DELIVERY
Peter Knauer
Xeris Pharmaceuticals
- Outlining the XeriJect platform for high-concentration large-molecule parenteral formulations
- Profiling device compatibility for XeriJect formulations, including autoinjectors for ease of use
- Displaying nonclinical delivery and stability data that demonstrate platform performance
10:35 - 10:40
Q&A SESSION ON XERIJECT FORMULATION PLATFORM
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
Sponsored By SFM MEDICAL DEVICES GmbH
11:00 - 11:25
ADVANCEMENTS IN GLOBAL DRUG DEVELOPMENT
Gurpreet Singh
IQVIA
- Prioritizing patient safety as the foundation for reliable, ethical, efficient development
- Harnessing real-world evidence to inform decisions, reduce risks, and speed approvals globally
- Transforming development with digital and AI technologies that shape future workflows
11:25 - 11:30
Q&A SESSION ON THE FUTURE OF DRUG DEVELOPMENT
11:30 - 11:55
FROM MOLECULE TO MARKET: ALGORITHM-BASED TOOLS IN STREAMLINING DRUG PRODUCT DEVELOPMENT
Damien Bellos
BASF
- Leveraging algorithm-based platforms for faster, smarter, predictive formulation strategies
- Exemplifying BASF’s ZoomLab for virtual screening and data-driven excipient–API design
- Accelerating development timelines while reducing complexity via precision decision support
11:55 - 12:00
Q&A SESSION ON ALGORITHM-BASED FORMULATION DEVELOPMENT
12:00 - 12:25
ODC™: A NAKED, TARGETED OLIGO MODALITY FOR PRECISION DELIVERY AND BBB-CROSSING RNA/DNA THERAPEUTICS
Zoya Gluzman-Poltorak
Forta Bio, Inc.
- Defining ODC as a naked, ligand-targeted oligonucleotide class designed for precision delivery
- Integrating TERT-activated cytotoxicity and programmable immunomodulation within the ODC platform
- Facilitating cell-specific uptake via CpG or aptamer ligands without vectors or encapsulation
- Crossing the BBB in preclinical glioma with aptamer-guided ODC and scalable IV CNS delivery
12:25 - 12:30
Q&A SESSION ON OLIGONUCLEOTIDE-DEPENDENT CYTOTOXICITY
12:30 - 13:30
NETWORKING LUNCH & VISITING THE DRUG DELIVERY EXHIBITION
13:30 - 13:55
INSTAPILL®: LYOPHILIZED ODT PLATFORM FOR WATER-FREE ORAL DELIVERY
Keith Dodson
InstaPill Private Limited
- Emphasizing instant disintegration of InstaPill ODTs for water-free dosing and better compliance
- Allowing pre-gastric uptake to improve bioavailability and reduce first-pass metabolism
- Ensuring taste masking, protein/peptide stability, and low excipient levels for pediatrics
13:55 - 14:00
Q&A SESSION ON LYOPHILIZED ODTS AND WATER-FREE DELIVERY
14:00 - 14:25
NATURAL NEUROTROPISM AS DRUG DELIVERY: LEVERAGING ZIKA VIRUS BIOLOGY TO OVERCOME THE BLOOD-BRAIN BARRIER IN GLIOBLASTOMA
Richard Rovin
UP Oncolytics
- Capitalizing on innate neurotropism to drive targeted delivery across the BBB in glioblastoma
- Contrasting natural-vector entry against engineered BBB-crossing tactics to reduce dose and risks
- Charting preclinical efficacy and a translational roadmap toward first-in-human evaluation
14:25 - 14:30
Q&A SESSION ON NEUROTROPIC BBB DELIVERY IN GLIOBLASTOMA
14:30 - 14:45
FEEDBACK AND RAFFLE DRAW
14:45 - 15:00
CLOSING REMARKS
Become a Speaker & Join the Conversation
SUBSCRIBE FOR UPDATES
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.